Axogen agreed to acquire Biocircuit Technologies for $200 million in cash, a deal intended to deepen its position in the peripheral nerve market by bringing Nerve Tape—an FDA-approved device for sutureless nerve repair—into Axogen’s portfolio. The acquisition is positioned as an adoption and expansion lever for Nerve Tape. Samsung Biologics also announced a $262 million manufacturing agreement with an unnamed European pharma firm, with manufacturing commitments through 2033 at the Songdo site in South Korea. The agreement further extends capacity and diversifies long-term customer programs, following expansion of Samsung Biologics’ U.S. footprint after acquiring a Rockville facility earlier in 2026. Finally, Revvity signed an agreement to acquire Human Cell Design to expand its human cell model capabilities, including beta cell models for diabetes and obesity research—expected to close in Q4 2026. These moves point to continued capital allocation toward both physical capacity and translational tooling needed for sustained pipeline development.